1. Ominsky M, Boyce RG, Kosteniuk P, et al 2013 Nf1 Continuous modeling-based bone formation: A novel mechanism that could explain the sustained increases in hip bone mineral density (BMD) with denosumab treatment. J Bone Miner Res 28 (Suppl 1). Available at Accessed November 15, 2013.
Reproduced with permission of the American Society of Bone and Mineral Research.

2. Zebaze RM, Libanati C, McClung MR, et al 2013 Denosumab reduces hip cortical porosity in women with osteoporosis. J Bone Miner Res 28 (Suppl 1). Available at Accessed November 15, 2013.
Reproduced with permission of the American Society of Bone and Mineral Research.

3. Leder B, Uihlein A, Tsai J, et al 2013 The DATA Extension Study: 2 years of combined denosumab and teriparatide in postmenopausal women with osteoporosis: A randomized controlled trial. J Bone Miner Res 28 (Suppl 1). Available at Accessed November 15, 2013.
Reproduced with permission of the American Society of Bone and Mineral Research.

4. Papapoulos S, Lippuner K, Roux C, et al 2013 Eight years of denosumab treatment in postmenopausal women with osteoporosis: Results from the first five years of the FREEDOM Extension. J Bone Miner Res 28 (Suppl 1). Available at Accessed November 15, 2013.
Reproduced with permission of the American Society of Bone and Mineral Research.